These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 21809041)

  • 1. The frontotemporal syndromes of ALS. Clinicopathological correlates.
    Strong MJ; Yang W
    J Mol Neurosci; 2011 Nov; 45(3):648-55. PubMed ID: 21809041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
    Takeda T
    Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
    JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment.
    Yang W; Strong MJ
    Amyotroph Lateral Scler; 2012 Feb; 13(2):178-93. PubMed ID: 22214313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration.
    Long Z; Irish M; Hodges JR; Halliday G; Piguet O; Burrell JR
    Neurobiol Aging; 2021 Nov; 107():11-20. PubMed ID: 34371283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
    Mann DMA; Snowden JS
    Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
    Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
    Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.
    Nakamura M; Bieniek KF; Lin WL; Graff-Radford NR; Murray ME; Castanedes-Casey M; Desaro P; Baker MC; Rutherford NJ; Robertson J; Rademakers R; Dickson DW; Boylan KB
    Acta Neuropathol; 2015 Jul; 130(1):145-57. PubMed ID: 25917047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.
    Carlos AF; Josephs KA
    J Neurol; 2022 Aug; 269(8):4030-4054. PubMed ID: 35320398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS.
    Ke YD; van Hummel A; Stevens CH; Gladbach A; Ippati S; Bi M; Lee WS; Krüger S; van der Hoven J; Volkerling A; Bongers A; Halliday G; Haass NK; Kiernan M; Delerue F; Ittner LM
    Acta Neuropathol; 2015 Nov; 130(5):661-78. PubMed ID: 26437864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
    Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments.
    Swarup V; Phaneuf D; Bareil C; Robertson J; Rouleau GA; Kriz J; Julien JP
    Brain; 2011 Sep; 134(Pt 9):2610-26. PubMed ID: 21752789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
    Wegorzewska I; Bell S; Cairns NJ; Miller TM; Baloh RH
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18809-14. PubMed ID: 19833869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
    Riku Y; Seilhean D; Duyckaerts C; Boluda S; Iguchi Y; Ishigaki S; Iwasaki Y; Yoshida M; Sobue G; Katsuno M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 2 Loci at chromosomes 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Gijselinck I; Engelborghs S; Maes G; Cuijt I; Peeters K; Mattheijssens M; Joris G; Cras P; Martin JJ; De Deyn PP; Kumar-Singh S; Van Broeckhoven C; Cruts M
    Arch Neurol; 2010 May; 67(5):606-16. PubMed ID: 20457961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TDP-43 variants of frontotemporal lobar degeneration.
    Bigio EH
    J Mol Neurosci; 2011 Nov; 45(3):390-401. PubMed ID: 21607722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [FTLD/ALS as TDP-43 proteinopathies].
    Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
    Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant.
    King A; Al-Sarraj S; Troakes C; Smith BN; Maekawa S; Iovino M; Spillantini MG; Shaw CE
    Acta Neuropathol; 2013 Feb; 125(2):303-10. PubMed ID: 23053136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.